XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings (Loss) Per Share
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share

14. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.

The calculations of earnings (loss) per share are as follows:

 

 

Year Ended December 31,

 

(In thousands, except per share amounts)

 

2021

 

 

2020

 

 

2019

 

Basic earnings (loss) per Common Share:

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations, net of tax

 

$

133,975

 

 

$

(132,619

)

 

$

(238,411

)

Net loss attributable to non-controlling interests

 

 

0

 

 

 

0

 

 

 

424

 

Net income (loss) from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders

 

 

133,975

 

 

 

(132,619

)

 

 

(237,987

)

Income from discontinued operations, net of tax

 

 

463

 

 

 

833,026

 

 

 

55,809

 

Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders

 

$

134,438

 

 

$

700,407

 

 

$

(182,178

)

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

130,140

 

 

 

159,281

 

 

 

166,306

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (loss) from continuing operations per Common Share

 

$

1.03

 

 

$

(0.83

)

 

$

(1.43

)

Basic earnings from discontinued operations per Common Share

 

$

0.00

 

 

$

5.23

 

 

$

0.33

 

Net earnings (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share

 

$

1.03

 

 

$

4.40

 

 

$

(1.10

)

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per Common Share:

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations, net of tax

 

$

133,975

 

 

$

(132,619

)

 

$

(238,411

)

Net loss attributable to non-controlling interests

 

 

0

 

 

 

0

 

 

 

424

 

Net income (loss) from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders

 

 

133,975

 

 

 

(132,619

)

 

 

(237,987

)

Income from discontinued operations, net of tax

 

 

463

 

 

 

833,026

 

 

 

55,809

 

Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders

 

$

134,438

 

 

$

700,407

 

 

$

(182,178

)

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

130,140

 

 

 

159,281

 

 

 

166,306

 

Plus: Dilutive effect of stock options, restricted stock unit awards and warrants

 

 

8,518

 

 

 

0

 

 

 

0

 

Weighted-average common shares outstanding assuming dilution

 

 

138,658

 

 

 

159,281

 

 

 

166,306

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) from continuing operations per Common Share

 

$

0.97

 

 

$

(0.83

)

 

$

(1.43

)

Diluted earnings from discontinued operations per Common Share

 

$

0.00

 

 

$

5.23

 

 

$

0.33

 

Net earnings (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share

 

$

0.97

 

 

$

4.40

 

 

$

(1.10

)

As a result of the loss from continuing operations, net of tax for the years ended December 31, 2020 and 2019, we used basic weighted-average common shares outstanding in the calculation of diluted earnings (loss) per share, since the inclusion of any stock equivalents would be anti-dilutive.

The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:

 

 

Year Ended December 31,

 

(In thousands)

 

2021

 

 

2020

 

 

2019

 

Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation

 

 

0

 

 

 

42,845

 

 

 

27,945